Investigation of the DNMT3B –579 G>T Promoter Polymorphism in Patients with Colorectal Cancer in an Azerbaijani Population

• DOI: 10.31557/apjcp.2022.23.6.1879
• Publication Date: 2022-06-28T19:01:22Z
• Authors: Bayram Bayramov; Nuru Bayramov; Hazi Aslanov; Mehraj Abbasov; Shabnam Mammadova; Khagani Eynullazada; Farah Gahramanova; Vugar Yagublu
• Keywords: Male; DNA Methyltransferase 3B; Azerbaijan; Polymorphism, Single Nucleotide; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Humans; Genetic Predisposition to Disease; DNA (Cytosine-5-)-Methyltransferases; Colorectal Neoplasms; Research Article

Objective: The main aim of the present study was to determine clinical significance DNA methyltransferase 3B (DNMT3B) gene –579 G>T polymorphism in colorectal cancer (CRC) patients. Methods: A total 140 patients with CRC and 164 healthy individuals were included study. According manufacturer’s instructions, isolated from blood, genotypes determined on agarose gel by PCR-RFLP method. Genotype confirmation performed using Sanger sequencing randomly selected samples. Results: When comparing case control groups, heterozygous GT (OR=0.53; 95% CI=0.32–0.88), under dominant model CI=0.33–0.87), mutant T allele (OR=0.71; CI=0.51–0.98) statistically associated a reduced risk CRC. However, when age, pathological tumor grade stage, smoking habit, alcohol consumption compared, no significant relationship (P>0.05). Furthermore, among males, (OR=0.40; CI=0.19–0.84). Conclusion: Our highlighted that DNMT3B plays protective role against development.